Mucommune
Dr. Sam Lai is a pharmacoengineering & molecular pharmaceutics professor at the University of North Carolina at Chapel Hill, and the founder of Mucommune. Dr. Lai's research interests include developing new technologies for vaccine development & delivery, as well as innovative approaches to target & treat infectious diseases. Sam has also developed new methods for tracking & analyzing immune responses to vaccination. Prior to their current positions, Dr. Lai was a research assistant professor at Johns Hopkins University, where they worked on developing new technologies for the delivery of vaccines & drugs.
Sam Lai's educational career began at Phillips Academy, Andover before studying Chemical & Biomolecular Engineering at Cornell University where they obtained their BS. Sam then continued their education at The Johns Hopkins University, completing a Ph.D. in Chemical & Biomolecular Engineering.
Some direct reports include Morgan Mcsweeney - Assistant Director of Development, Thomas Moench - VP, Clinical Development, and Richard Cone - President.
This person is not in any offices
Mucommune
Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform developed at Johns Hopkins University and University of North Carolina at Chapel Hill.